Results 1 to 10 of about 3,329 (168)

Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells [PDF]

open access: yesScientific Reports, 2017
HIV prevention research is focused on combining antiretrovirals (ARV) and progestin contraceptives to prevent HIV infection and pregnancy. The possibility that progestins compromise ARV anti-HIV activity prompted us to evaluate the effects of progestins ...
Mickey V Patel   +2 more
exaly   +4 more sources

Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner

open access: yesEBioMedicine, 2015
Tenofovir (TFV) is used in combination with other antiretroviral drugs for human immunodeficiency virus (HIV) treatment and prevention. TFV requires two phosphorylation steps to become pharmacologically active; however, the kinases that activate TFV in ...
Elaine E To, Craig W Hendrix, Julie Lade
exaly   +3 more sources

Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue

open access: yesPharmaceutics, 2022
Background: HIV-1 pre-exposure prophylaxis (PrEP) has focused predominantly on protective efficacy in receptive sex, with limited research on the dosing requirements for insertive sex.
Laura Else   +12 more
doaj   +1 more source

Tenofovir vaginal film as a potential MPT product against HIV-1 and HSV-2 acquisition: formulation development and preclinical assessment in non-human primates

open access: yesFrontiers in Reproductive Health, 2023
Tenofovir (TFV) is an adenosine nucleotide analog with activity against HIV and HSV-2. Secondary analyses of clinical trials evaluating TFV gel as pre-exposure prophylaxis (PrEP) for HIV have shown that gel formulations of TFV provide significant ...
Sravan Kumar Patel   +12 more
doaj   +1 more source

Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study

open access: yesPLoS ONE, 2022
Multipurpose prevention technologies (MPTs), which prevent sexually transmitted infection(s) and unintended pregnancy, are highly desirable to women.
Andrea R. Thurman   +18 more
doaj   +2 more sources

Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring

open access: yesFrontiers in Cellular and Infection Microbiology, 2022
BackgroundA relationship between the vaginal microbiota and tenofovir (TFV) concentrations and activity after topical administration has been previously reported.ObjectiveCONRAD A15-138 was a randomized, placebo-controlled Phase I study aimed at ...
Andrea R. Thurman   +8 more
doaj   +1 more source

Effect of tenofovir on nucleotidases and cytokines in HIV-1 target cells. [PDF]

open access: yesPLoS ONE, 2013
Tenofovir (TFV) has been widely used for pre-exposure prophylaxis of HIV-1 infection with mixed results. While the use of TFV in uninfected individuals for prevention of HIV-1 acquisition is actively being investigated, the possible consequences of TFV ...
Nabanita Biswas   +6 more
doaj   +1 more source

Trunk fat volume can be a predictor of postoperative complications after gastrectomy: a retrospective cohort study

open access: yesBMC Surgery, 2021
Background Obesity can affect postoperative outcomes of gastrectomy. Visceral fat area is superior to body mass index in predicting postoperative complications. However, visceral fat area measurement is time-consuming and is not optimum for clinical use.
Shinichiro Shiomi   +9 more
doaj   +1 more source

Genital microbiota of women using a 90 day tenofovir or tenofovir and levonorgestrel intravaginal ring in a placebo controlled randomized safety trial in Kenya

open access: yesScientific Reports, 2022
In a phase-IIa trial, we investigated the influence of 90 days continuous-delivery tenofovir (TFV) intravaginal rings (IVRs) with/without levonorgestrel (LNG) on the genital microbiota of Kenyan women.
Smritee Dabee   +19 more
doaj   +1 more source

Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya

open access: yesFrontiers in Reproductive Health, 2023
IntroductionGlobally, many young women face the overlapping burden of HIV infection and unintended pregnancy. Protection against both may benefit from safe and effective multipurpose prevention technologies.MethodsHealthy women ages 18–34 years, not ...
Nelly R. Mugo   +29 more
doaj   +1 more source

Home - About - Disclaimer - Privacy